• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:刘艳鑫,吕晓霖,于宸,刘安昌.贝伐珠单抗生物类似药与原研药治疗晚期NSCLC的临床综合评价[J].药学研究,2026,45(1):96-102[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 3372次   下载 844次 本文二维码信息
码上扫一扫!
贝伐珠单抗生物类似药与原研药治疗晚期NSCLC的临床综合评价
刘艳鑫,吕晓霖,于宸,刘安昌
字体:加大+|默认|缩小-
(山东大学齐鲁医院药剂科<临床药学部>,山东 济南 250012)
摘要:
目的 基于真实世界数据对贝伐珠单抗生物类似药安可达和原研药安维汀治疗晚期非小细胞肺癌(NSCLC)开展临床综合评价。方法 构建药品临床综合评价指标体系,基于真实世界数据,结合药品说明书信息、相关循证指南、临床研究文献等,从有效性、安全性、经济性、可及性、创新性和适宜性6个维度,对安维汀和安可达各指标进行定性、定量整合分析。结果 在有效性和安全性方面,临床试验及相关研究均表明安可达与安维汀在有效性和总体安全性上表现相似,本研究纳入的两组病例在客观缓解率(44.3% VS 39.2%)、疾病控制率(72.6% VS 82.1%)、不良反应发生率(45.3% VS 51.8%)等方面差异均无统计学意义。在经济性与可及性方面,安可达组成本-效果比优于安维汀组(2 294.4元/% VS 3 125.0元/%),其单位剂量价格明显更低(1 126元/100 mg VS 1 500元/100 mg),年度药费占居民可支配收入比例也明显更低(57.80% VS 96.25%),且在各级医疗机构中的配备结构更优。在适宜性与创新性方面,安可达在关键质量属性及临床适用性方面与安维汀高度一致,同时实现了生产工艺的深度优化和创新,二者共同推动贝伐珠单抗在国内的临床普及与深度应用。结论 与安维汀相比,安可达治疗晚期NSCLC在有效性、安全性、适宜性维度具有高度相似性,在经济性和可及性维度具有明显优势,创新性互补。
关键词:  非小细胞肺癌  贝伐珠单抗  生物类似药  临床综合评价
DOI:10.13506/j.cnki.jpr.2026.01.014
基金项目:山东省医学会临床科研资金—齐鲁专项(No.YXH2022ZX02053)
出版日期:2026-01-26
Comprehensive clinical evaluation of a Bevacizumab biosimilar and the originator drug for advanced non-small cell lung cancer
LIU Yanxin,LYU Xiaolin,YU Chen,LIU Anchang
(Department of Pharmacy, Qilu Hospital of Shandong University, Jinan 250012, China)
Abstract:
Objective To conduct a comprehensive clinical evaluation of the bevacizumab biosimilar (Ankeda) and the originator drug (Avastin) for the treatment of advanced non-small cell lung cancer (NSCLC).Methods According to the drug instructions, evidence-based guidelines and clinical research literature, Ankeda and Avastin were evaluated across six dimensions based on real-world data.Results In terms of efficacy and safety, published studies demonstrated that Ankeda and Avastin were comparable. There were no significant differences in ORR (44.3% VS 39.2%), DCR (72.6% VS 82.1%), or the incidence of adverse reactions (45.3% VS 51.8%) between the two patient groups. Compared to Avastin, the Ankeda group showed advantages in economy, with a lower cost-effectiveness ratio (2 294.4 VS 3 125.0), a lower unit dose price (1 126 CNY VS 1 500 CNY), and a lower proportion of annual drug cost to residents' disposable income (57.80% VS 96.25%). The allocation and configuration of Ankeda was also found to be superior to that of Avastin in public medical institutions. In terms of suitability, Ankeda was highly consistent with Avastin in both critical quality attributes and clinical use. Furthermore, Ankeda has achieved significant optimization and innovation in its production process, and together with Avastin, has promoted the widespread clinical adoption and application of bevacizumab in China.Conclusion Compared to Avastin, Ankeda shows no significant differences in efficacy, safety , suitability for the treatment of advanced NSCLC, while demonstrating significant advantages in economy and accessibility.
Key words:  Non-small cell lung cancer  Bevacizumab  Biosimilar drug  Comprehensive clinical evaluation
今日访问量:2273    总访问量:55338614
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司